Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

NCT01656161 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Triptorelin embonate 22.5 mg

Sponsor

Debiopharm International SA

Collaborators

[object Object]